Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

544
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
544
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

591
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
591
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Best practices for the care of pregnant people living with TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2023
Same author

Effectiveness of the short-term use of <i>Cimicifuga racemosa</i> in the endothelial function of postmenopausal women: a double-blind, randomized, controlled trial.

Climacteric : the journal of the International Menopause Society·2019
Same author

Time since menopause, but not age, is associated with increased risk of osteoporosis.

Climacteric : the journal of the International Menopause Society·2019
Same author

Does freeze-all policy affect IVF outcome in poor ovarian responders?

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2017
Same author

Effect of short-term estrogen therapy on endothelial function: a double-blinded, randomized, controlled trial.

Climacteric : the journal of the International Menopause Society·2016
Same author

Intracytoplasmic sperm injection outcomes with cryopreserved testicular sperm aspiration samples.

Andrologia·2015

Related Experiment Video

Updated: Mar 23, 2026

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-&#946; Signaling
07:49

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling

Published on: August 3, 2018

11.9K

Short-term tibolone does not interfere with endothelial function: a double-blinded, randomized, controlled trial.

M F S Celani1, R Hurtado1, A H F Brandão1

  • 1a Department of Obstetrics and Gynecology of the Universidade Federal de Minas Gerais , Belo Horizonte , Brazil.

Climacteric : the Journal of the International Menopause Society
|April 1, 2016
PubMed
Summary

Short-term hormone replacement therapy with tibolone did not improve endothelial function in healthy postmenopausal women. Flow-mediated dilation (FMD) measurements showed no significant changes after 28 days of tibolone treatment compared to placebo.

Keywords:
Tibolonebrachial arteryendothelial functionflow-mediated dilationpostmenopausal

More Related Videos

A Rat Model of Tibial Cortex Transverse Transport for the Treatment of Lower Limb Ischemia
09:56

A Rat Model of Tibial Cortex Transverse Transport for the Treatment of Lower Limb Ischemia

Published on: March 6, 2026

354
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Related Experiment Videos

Last Updated: Mar 23, 2026

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-&#946; Signaling
07:49

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling

Published on: August 3, 2018

11.9K
A Rat Model of Tibial Cortex Transverse Transport for the Treatment of Lower Limb Ischemia
09:56

A Rat Model of Tibial Cortex Transverse Transport for the Treatment of Lower Limb Ischemia

Published on: March 6, 2026

354
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Area of Science:

  • Endocrinology
  • Cardiovascular Health
  • Women's Health

Background:

  • Menopause is associated with increased cardiovascular risk.
  • Hormone replacement therapy (HRT) is used to manage menopausal symptoms.
  • Endothelial dysfunction is an early marker of atherosclerosis.

Purpose of the Study:

  • To assess the impact of short-term tibolone therapy on endothelial function.
  • To evaluate changes in flow-mediated dilation (FMD) of the brachial artery.
  • To determine if tibolone improves endothelial-dependent vasodilation in postmenopausal women.

Main Methods:

  • Randomized, double-blinded, placebo-controlled trial.
  • 100 healthy postmenopausal women received tibolone (2.5 mg/day) or placebo for 28 days.
  • Brachial artery FMD measured before and after treatment.

Main Results:

  • Baseline FMD measurements were similar between tibolone and placebo groups.
  • No significant differences in FMD values were observed post-treatment in either group.
  • The number of women showing FMD improvement was comparable between groups.

Conclusions:

  • Tibolone (2.5 mg/day) for 28 days does not enhance endothelial function in healthy postmenopausal women.
  • No significant endothelial-dependent vasodilation was detected via FMD.
  • Short-term tibolone therapy does not appear to benefit vascular health in this population.